Intel Corporation (NASDAQ:INTC) on 2 February has signed a definitive agreement to acquire Lantiq, a leading supplier of broadband access and home networking technologies. The transaction is subject to customary closing conditions and regulatory approvals. The transaction is expected to close in approximately 90 days. Deal terms were not disclosed. On Wednesday shares of Intel Corporation (NASDAQ:INTC) closed at $33.60. Company’s sales growth for last 5 years was 9.70% and EPS growth for next 5 years is recorded as 9.00%.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), announced that it has commenced an underwritten public offering of up to $125,000,000 of shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $18,750,000 of shares of common stock at the public offering price, less the underwriting discount. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in last trading activity fell -4.08% to close at $55.23. Company weekly performance is -1.57% while its quarterly performance stands at 23.28%. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is -20.84% away from its 52 week high.
Zacks upgraded shares of NxStage Medical (NASDAQ:NXTM) from a neutral rating to an outperform rating in a research note released on Wednesday morning. They currently have $20.50 target price on the stock. On last trading day Nxstage Medical, Inc. (NASDAQ:NXTM) fell -0.06% to close at $17.68. Its volatility for the week is 3.29% while volatility for the month is 2.97%. NXTM’s sales growth for past 5 years was 15.40% and its EPS growth for past 5 years was 24.10%. Nxstage Medical, Inc. (NASDAQ:NXTM) monthly performance is 1.73%.
Acadia Realty Trust (NYSE:AKR), will release its fourth quarter 2014 earnings on Tuesday, February 17, 2015 after market close. The Company will conduct a conference call the following day, Wednesday, February 18, 2015 at 12:00 PM ET to discuss its quarterly results.
Acadia Realty Trust (NYSE:AKR) has 0.60% insider ownership while its institutional ownership stands at 95.50%. In last trading activity company’s stock closed at $36.43.
Esperion Therapeutics (NASDAQ:ESPR) on 2 January announced that the FDA has removed the peroxisome proliferator-activated receptor partial clinical hold on ETC-1002. On last trading day Esperion Therapeutics, Inc. (NASDAQ:ESPR) increased 6.24% to close at $55.01. Its volatility for the week is 10.92% while volatility for the month is 8.86%. ESPR’s EPS growth for past 5 years was -29.50%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) monthly performance is 24.49%.